The Malmberg lab partner in major cancer immunotherapy project
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
Katona BW, Lubinski J, Pal T, Huzarski T, Foulkes WD, Moller P, Eisen A, Randall Armel S, Neuhausen SL, Raj R, Aeilts A, Singer CF, Bordeleau L, Karlan B, Olopade O, Tung N, Zakalik D, Kotsopoulos J, Fruscio R, Eng C, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group(2024) The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation Cancer(in press) DOI 10.1002/cncr.35666, PubMed 39611336
Pölöske D, Sorger H, Schönbichler A, de Araujo ED, Neubauer HA, Orlova A, Timonen SH, Abdallah DI, Ianevski A, Kuusanmäki H, Surbek M, Heyes E, Eder T, Wagner C, Suske T, Metzelder ML, Bergmann M, Dahlhoff M, Grebien F, Fleck R, Pirker C, Berger W, Hadzijusufovic E, Sperr WR, Kenner Let al.(2024) Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma Hemasphere, 8(12), e70001 DOI 10.1002/hem3.70001, PubMed 39619245